UCB Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
UCB Stock Forecast and Price Target
Year-long price target forecasts from seven prominent analysts have recently been released for UCB, with an average price target of 125.00€. This potential loss of -0.08 percent from the previous closing price in April, 2024 is calculated on a high forecast of 164.00€ and a low estimate of 70.00€. Even if you are not interested in UCB stock, you should be aware of its competitors and their current standings.
-0.08% Downside
UCB Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, UCB's Price has decreased by 100.00%, going from 86.56€ to 0.00€. In the next year, analysts expect Fair Value to reach 75.74€ – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$724.87 | Buy/Sell | $636.99 | 15.54% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.82 | Buy/Sell | $174.55 | 15.79% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$130.72 | Buy/Sell | $130.51 | 7.10% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$167.29 | Buy/Sell | $178.42 | 12.98% |
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$571.73 | Buy/Sell | $591.94 | 7.57% |
UCB Revenue Forecast for 2023 - 2025 - 2030
In the last three years, UCB's Revenue has decreased by 3.09%, going from 5.35€B to 5.18€B. In the next year, analysts expect Revenue to reach 5.64€B – an increase of 8.78%. For the next seven years, the forecast is for Revenue to grow by 53.78%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF90.00 | Buy/Sell | CHF105.00 | 19.58% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$269.38 | Buy/Sell | $303.65 | 17.77% |
| SAN Stock Forecast | Sanofi | Outperform |
16
|
91.62€ | Buy/Sell | 102.80€ | 18.97% |
.jpg)
UCB Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, UCB's Dividend per Share has grown, increasing from 1.27€ to 1.36€ – a growth of 7.09%. The next year looks promising for UCB, with analysts predicting Dividend per Share of 1.47€ – an increase of 8.09%. Over the next seven years, experts anticipate that UCB's Dividend per Share will grow at a rate of 15.44%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.70 | Buy/Sell | $58.15 | 21.92% |
| CSL Stock Forecast | CSL | Outperform |
12
|
$278.45 | Buy/Sell | $205.51 | -27.04% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.27 | Buy/Sell | $87.82 | 22.57% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SHW Stock Forecast | Sherwin Williams | Outperform |
15
|
$304.81 | Buy/Sell | $317.38 | 11.37% |
| LONN Stock Forecast | Lonza Group | Buy |
16
|
CHF513.80 | Buy/Sell | CHF516.89 | 13.86% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.09k | Buy/Sell | ¥4.74k | 11.25% |
UCB EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, UCB's EBITDA has decreased from 1.40€B to 1.27€B – a 9.49% drop! Next year, analysts are expecting EBITDA to reach 1.45€B – an increase of 14.63%. Over the next seven years, the forecast is for EBITDA to grow by 85.66%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PPG Stock Forecast | PPG Industries | Outperform |
13
|
$129.23 | Buy/Sell | $159.04 | 23.19% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.25 | Buy/Sell | $11.59 | 20.75% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$51.18 | Buy/Sell | $77.05 | 50.84% |
UCB EBIT Forecast for 2023 - 2025 - 2030
In the last three years, UCB has seen a decline in its EBIT, from 1.10€B to 578.00€M – a 47.26% decrease. For next year, analysts predict EBIT of 869.77€M, which would mean an increase of 50.48%. Over the next seven years, experts predict that UCB's EBIT will grow at a rate of 323.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4523 Stock Forecast | Eisai | Outperform |
18
|
¥6.26k | Buy/Sell | ¥9.58k | 34.21% |
| CRDA Stock Forecast | Croda International Plc | Outperform |
18
|
£46.49 | Buy/Sell | £65.12 | 9.70% |
| APLS Stock Forecast | Apellis Pharmaceuticals | Outperform |
6
|
$47.93 | Buy/Sell | $79.81 | 73.59% |
UCB EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, UCB's EPS has decreased by 100.00%, going from 5.36€ to 0.00€. In the next year, analysts expect EPS to reach 4.69€ – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| WCH Stock Forecast | Wacker Chemie | Outperform |
17
|
101.85€ | Buy/Sell | 145.36€ | 22.73% |
| CLN Stock Forecast | Clariant | Outperform |
18
|
CHF13.02 | Buy/Sell | CHF16.11 | 15.21% |
| OMER Stock Forecast | Omeros | Hold |
11
|
$3.06 | Buy/Sell | $13.00 | -100.00% |
.jpg)